Entering text into the input field will update the search result below

Positive results from Humanigen's lenzilumab study in COVID-19 published in The Lancet

Dec. 02, 2021 2:50 AM ETHumanigen, Inc. (HGEN)By: SA News Team

Coronavirus and DNA, virus mutation. New variant and strain of SARS CoV 2. Microscopic view.

Gilnature/iStock via Getty Images

  • Humanigen (NASDAQ:HGEN) announces that The Lancet has published positive results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalised COVID-19 patients.
  • The Lancet paper concludes “LIVE-AIR showed that lenzilumab treatment of hospitalised patients with COVID-19

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.